CORRESPONDENCE
We read the Review by Giannitsis and Katus (Giannitsis, E. & Katus, H. Cardiac tro ponin level elevations not related to acute coronary syndromes. Nat. Rev. Cardiol. 10, 623-634 [2013] ) 1 with great interest. We believe that a few points need to be discussed in greater detail. We were sur prised to note the absence of any mention of amyloid osis among the chronic con ditions not related to acute coronary syn drome (ACS) that can be associated with substantial e levation in cardiac tr oponin (cTn) levels.
Light chain amyloidosis is a plasma cell dyscrasia characterized by extra cellular dep osition of toxic βfibrillar immuno globulin light chain in several organs, includ ing the heart.
2 Cardiac biomarkers, including cTn, have been studied exten sive ly in light chain amyloidosis, because cardiac involve ment is the mostimportan t determinant of clinical outcome.
3 Persist ently elevated cTn levels are frequently found in patients with amyloidosis, and are an indication of cardiac amyloid infiltration.
2 In our experi ence, cTnI levels >0.09 μg/l at presentation were recorded in 34% of 64 patients with light chain amyloid osis, and in 58% of 38 patients with transthyretinrelated cardiac amyloid osis (F. Perfetto, unpublished work). Notably, patients with amyloidosis often present with misleading symptoms and signs, such as chest pain or a psuedoinfarc tion pattern (QS waves in consecutive leads) on the electrocardiogram, which can suggest a diagnosis of ischaemic heart disease, as well as regional radio nuclide uptake defects on myo cardial perfusion scintigraphy, owing to severe, localized amyloid infil tration. Patients with cardiac amyloidosis, therefore, often undergo unnecessary cor onary angio graphy, which usually shows normal epicardial arteries.
3-5 Interestingly, serial cTn assays in patients with amyloid osis do not show a crescendo-decrescendo pattern of elevation. 6 This feature distin guishes a myloidosis from other causes of cTn elevation.
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Federico Perfetto, Franco Bergesio, Michele Emdin and Francesco Cappelli cTn level is also a prognostic factor in cardiac light chain amyloidosis. A cTnT level >0.035 g/l accurately predicts poor survival, 7 and patients with cTnT >0.060 g/l or cTnI >0.10 μg/l have an increased risk of mortality associated with blood stem cell transplantation, despite adjustment of melphalan dose. 7, 8 In a cohort of 76 con secutive patients with cardiac light chain amyloidosis, we found that cTnI ≥0.085 μg/l predicted right ventricular amyloid involve ment, an independent negative prognostic factor.
9 Interestingly, these data show that cTnI has greater specificity and sensitiv ity than Nterminal proBtype natriuretic peptide for predicting right ventricular dysfunction.
9
The exact pathological mechanism of cTn release in patients with amyloidosis is uncertain, but is likely to be multifactorial, including microvascular ischaemia, the mechanical effects of amyloid infiltration, and the proinflammatory or toxic effects of the amyloid protein or its precursor, leading to myocardial cell damage with membrane leakage and troponin release. 10 The pres ence of late gadolinium enhancement on cardiac MRI in patients with amyloid osis has been associated with increased cTn levels, suggesting a correlation between biomarker elevation and advanced amyloid infiltration.
11 For these reasons, we believe that amyloidosis should be included among the conditions not related to ACS that are associated with chronically elevated cTn levels.
Future perspectives for the use of cTn assays in the setting of amyloidosis include screening for silent cardiac involvement in patients with conditions that confer a high risk of developing cardiac amyloid osis, such as monoclonal gammo pathies of undetermined significance, or carrier s of amy loido genic mutation; for determinin g optimal treatment; and for evaluating resp on ses to therapy. Studies addressing these specific applications of cTn m easurement are needed. 
